388 related articles for article (PubMed ID: 18972226)
1. Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy.
Thrailkill KM; Clay Bunn R; Fowlkes JL
Endocrine; 2009 Feb; 35(1):1-10. PubMed ID: 18972226
[TBL] [Abstract][Full Text] [Related]
2. Matrix Metalloproteinases in Renal Diseases: A Critical Appraisal.
Zakiyanov O; Kalousová M; Zima T; Tesař V
Kidney Blood Press Res; 2019; 44(3):298-330. PubMed ID: 31185475
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease.
Raffetto JD; Khalil RA
Biochem Pharmacol; 2008 Jan; 75(2):346-59. PubMed ID: 17678629
[TBL] [Abstract][Full Text] [Related]
4. Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges.
Dimas GG; Didangelos TP; Grekas DM
Curr Vasc Pharmacol; 2017; 15(6):557-565. PubMed ID: 28155628
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases in tumour invasion and metastasis.
Curran S; Murray GI
J Pathol; 1999 Nov; 189(3):300-8. PubMed ID: 10547590
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases (MMPs) in health and disease: an overview.
Malemud CJ
Front Biosci; 2006 May; 11():1696-701. PubMed ID: 16368548
[TBL] [Abstract][Full Text] [Related]
7. Roles of Matrix Metalloproteinases and Their Natural Inhibitors in Metabolism: Insights into Health and Disease.
Molière S; Jaulin A; Tomasetto CL; Dali-Youcef N
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445827
[TBL] [Abstract][Full Text] [Related]
8. The functional balance of metalloproteinases and inhibitors in tissue degradation: relevance to oral pathologies.
Reynolds JJ; Meikle MC
J R Coll Surg Edinb; 1997 Jun; 42(3):154-60. PubMed ID: 9195805
[TBL] [Abstract][Full Text] [Related]
9. Calprotectin inhibits matrix metalloproteinases by sequestration of zinc.
Isaksen B; Fagerhol MK
Mol Pathol; 2001 Oct; 54(5):289-92. PubMed ID: 11577169
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases and diabetic vascular complications.
Kadoglou NP; Daskalopoulou SS; Perrea D; Liapis CD
Angiology; 2005; 56(2):173-89. PubMed ID: 15793607
[TBL] [Abstract][Full Text] [Related]
11. Biochemical and Biological Attributes of Matrix Metalloproteinases.
Cui N; Hu M; Khalil RA
Prog Mol Biol Transl Sci; 2017; 147():1-73. PubMed ID: 28413025
[TBL] [Abstract][Full Text] [Related]
12. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.
Liu J; Khalil RA
Prog Mol Biol Transl Sci; 2017; 148():355-420. PubMed ID: 28662828
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of irregular bleeding with hormone therapy: the role of matrix metalloproteinases and their tissue inhibitors.
Hickey M; Crewe J; Mahoney LA; Doherty DA; Fraser IS; Salamonsen LA
J Clin Endocrinol Metab; 2006 Aug; 91(8):3189-98. PubMed ID: 16684831
[TBL] [Abstract][Full Text] [Related]
14. Early events of overused supraspinatus tendons involve matrix metalloproteinases and EMMPRIN/CD147 in the absence of inflammation.
Attia M; Huet E; Gossard C; Menashi S; Tassoni MC; Martelly I
Am J Sports Med; 2013 Apr; 41(4):908-17. PubMed ID: 23404084
[TBL] [Abstract][Full Text] [Related]
15. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
[TBL] [Abstract][Full Text] [Related]
16. Role of metalloproteases and inhibitors in the occurrence and progression of diabetic renal lesions.
Zaoui P; Cantin JF; Alimardani-Bessette M; Monier F; Halimi S; Morel F; Cordonnier D
Diabetes Metab; 2000 Jul; 26 Suppl 4():25-9. PubMed ID: 10922970
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs.
Jabłońska-Trypuć A; Matejczyk M; Rosochacki S
J Enzyme Inhib Med Chem; 2016; 31(sup1):177-183. PubMed ID: 27028474
[TBL] [Abstract][Full Text] [Related]
18. [Role of matrix metalloproteinases (MMP) and their tissue inhibitors (TIMP) in nephrology].
Wasilewska A; Taranta-Janusz K; Zoch-Zwierz W; Rybi-Szumińska A; Kołodziejczyk Z
Przegl Lek; 2009; 66(9):485-90. PubMed ID: 21033407
[TBL] [Abstract][Full Text] [Related]
19. Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy.
McLennan SV; Fisher E; Martell SY; Death AK; Williams PF; Lyons JG; Yue DK
Kidney Int Suppl; 2000 Sep; 77():S81-7. PubMed ID: 10997695
[TBL] [Abstract][Full Text] [Related]
20. [Role of matrix metalloproteinases in the progression of renal lesions].
Marti HP
Presse Med; 2000 Apr; 29(14):811-7. PubMed ID: 10816726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
